The latest pharmacotherapeutic options for the treatment of IgA nephropathy in the pediatric population

ABSTRACT Introduction Despite the fact that IgA nephropathy (IgAN) is the most common chronic glomerulonephritis across the age spectrum worldwide, there is a lack of evidence-based treatment recommendations for pediatric patients. Moreover, current treatment options in children are very limited. This review aims to provide a comprehensive overview of current therapeutic strategies for managing IgAN, with a particular focus on new drugs recently evaluated in adult cohorts, as well as novel treatments reported in pediatric case studies. Areas covered A literature search was conducted using Pubmed and Scopus, covering the period from January 2013 to June 2025. Studies relevant to topic were included. Currently, there are numerous adult trials studying medications that target fundamental IgAN pathogenetic pathways, with very promising results in terms of proteinuria reduction and stabilization of kidney function. Expert opinion The higher disease activity and longer life expectancy in pediatric patients create a critical need for the evaluation of modern therapies in children with IgAN. Thus, it is crucial to prioritize pediatric clinical trials and to focus on removing the barriers that limit their implementation.